Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This open-label, single arm study will evaluate the efficacy and safety of anti-PD-1 antibody
in combination with pegaspargase in treatment of newly diagnosed advanced stage NK/T-cell
lymphoma.